China Resources Boya completes 80% equity sale of Boyaxinhe

China Resources Boya Bio-Pharmaceutical Group Co., Ltd. announced the completion of the transfer of an 80% equity interest in Jiangxi Boyaxinhe Pharmaceutical Co., Ltd. This follows the disclosure on July 21, 2025, regarding the progress and transaction results for the publicly listed transfer of the 80% equity interest.

The company signed an "Equity Transaction Contract" with Fuzhou High-tech Zone Cai Investment Group Co., Ltd., transferring the 80% equity stake in Boyaxinhe to Fuzhou High-tech Zone Cai Investment Group Co., Ltd.

As of September 8, 2025, the company received a "Company Change Notice" from Boyaxinhe, confirming the completion of industrial and commercial registration procedures related to the equity transfer. Post-transfer, the company directly holds 10.6869% of Boyaxinhe's equity, and its wholly-owned subsidiary, Jiangxi Boya Medical Investment Co., Ltd., holds 9.3131% of Boyaxinhe's equity. Consequently, Boyaxinhe will no longer be included in the company's consolidated financial statements.